Description
Complement component 5 (C5) inhibition therapies have been available for patients with generalized Myasthenia Gravis (gMG) in the United States since the introduction of Soliris® in late 2017. Alexion is developing potential new therapies that leverage a similar mechanism of action and are currently being tested in randomized controlled clinical trials. A need exists for the collection of real-world data on effectiveness, safety, and patterns of drug utilization for these drugs in the indicated population to complement the body of scientific evidence and better inform current and future clinical practice. Currently, there is no data source that collects adequate data on patients with gMG treated with Alexion C5 inhibition therapy (ALXN-C5IT) in the standard clinical practice setting in the US.
